IDO1 and melanoma: Although the inhibition of IDO with epacadostat in combination with pembrolizumab failed in improving melanoma patients outcome [225], other phase III studies on pembrolizumab plus epacadostat showed a higher response rate in different solid tumors, as compared to control groups (NCT03361865; NCT03374488; NCT03260894; NCT03358472).